Meta-Analysis of Maternal and Neonatal Outcomes Associated with the Use of Insulin Glargine versus NPH Insulin during Pregnancy

Abstract EN

As glargine, an analog of human insulin, is increasingly used during pregnancy, a meta-analysis assessed its safety in this population.

A systematic literature search identified studies of gestational or pregestational diabetes comparing use of insulin glargine with human NPH insulin, with at least 15 women in both arms.

Data was extracted for maternal outcomes (weight at delivery, weight gain, 1st/3rd trimester HbA1c, severe hypoglycemia, gestation/new-onset hypertension, preeclampsia, and cesarean section) and neonatal outcomes (congenital malformations, gestational age at delivery, birth weight, macrosomia, LGA, 5 minute Apgar score >7, NICU admissions, respiratory distress syndrome, neonatal hypoglycemia, and hyperbilirubinemia).

Relative risk ratios and weighted mean differences were determined using a random effect model.

Eight studies of women using glargine (331) or NPH (371) were analyzed.

No significant differences in the efficacy and safety-related outcomes were found between glargine and NPH use during pregnancy.